Correspondence

References

• Furlong M, Leggatt M. Reconciling the patient's right to confidentiality and the family's need to know. Australian and New Zealand Journal of Psychiatry 1996; 30: 614–622
   PubMed Web of Science ®Google Scholar
• Crampton EL, Glass RC, Marchant B, Reiss JA. Chemical ionisation mass fragmentographic measurement of dothiepin plasma concentrations following a single oral dose in man. Journal of Chromatography 1980; 183: 141–148
   Google Scholar
• Bertilsson L, Aberg-Wisted TA, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Therapeutic Drug Monitoring 1985; 7: 478–480
   PubMed Web of Science ®Google Scholar
• Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584–586
   PubMed Web of Science ®Google Scholar
• Heim M, Myere UA. Genotyping of poor metabolisers of debrisoquine by allele-specific amplification. Lancet 1990; 336: 529–532
   PubMed Web of Science ®Google Scholar
• Myer UA, Amrein R, Balant LP, et al. Antidepressants and drug-metabolising enzymes—expert group report. Acta Psychiatrica Scandinavica 1996; 93: 71–79
   Google Scholar
• Patton G. An epidemiological case for a separate adolescent psychiatry. Australian and New Zealand Journal of Psychiatry 1996; 30: 563–566
   PubMed Web of Science ®Google Scholar
• Hall GS. Adolescence: its psychology and its relations to physiology, anthropology, sociology, sex, crime, religion and education. Sidney Appleton, London 1905
   Google Scholar
• Feldman SS, Elliot GR. At the threshold: the developing adolescent. Harvard University Press, Cambridge, MA 1990
   Google Scholar
• Jones P, Rodgers B, Murray R, Marmot M. Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994; 344: 1398–1402
   PubMed Web of Science ®Google Scholar
• Chatterton R, Cardy S, Schramm TM. Neuroleptic malignant syndrome and clozapine monotherapy. Australian and New Zealand Journal of Psychiatry 1996; 30: 692–693
   PubMed Web of Science ®Google Scholar
• Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuropleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 1986; 143: 1227–1233
   PubMed Web of Science ®Google Scholar
• Levenson JL. Neuroleptic malignant syndrome. American Journal of Psychiatry 1985; 142: 1137–1145
   PubMed Web of Science ®Google Scholar
• Rosebush P, Stewart TA. Prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry 1989; 146: 717–725
   PubMed Web of Science ®Google Scholar
• Velamor VR, Swamy GN, Parmar RS, Williamson P, Caroff SN. Management of suspected neuroleptic malignant syndrome. Canadian Journal of Psychiatry 1995; 40: 545–550
   Google Scholar
• Reilly JJ, Crowe SF, Lloyd JH. Neuroleptic toxicity syndrome: a clinical spectrum. Australian and New Zealand Journal of Psychiatry 1991; 25: 499–505
   PubMed Web of Science ®Google Scholar
• Caroff SN, Mann SC, Lazarus A. Neuroleptic malignant syndrome: diagnostic issues. Psychiatric Annals 1991; 21: 130–147
   Web of Science ®Google Scholar
• Modestin J, Toffler G, Drescher JP. Neuroleptic malignant syndrome: results of a prospective study. Psychiatric Research 1992; 44: 251–256
   Google Scholar
• Velamor VR, Norman R MG, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. Journal of Nervous and Mental Diseases 1994; 182: 168–173
   Google Scholar
• Goats MG, Escobar JL. An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of a clozapine therapy: report of a case and results of a clozapine rechallenge. Journal of Clinical Psychopharmacology 1992; 12: 139–140
   Google Scholar
• Adityanjee SinghS, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. British Journal of Psychiatry 1988; 153: 107–111
   PubMedGoogle Scholar
• Nopoulos P, Flaum M, Miller DD. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Annals of Clinical Psychiatry 1990; 2: 251–253
   Google Scholar
• Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Journal of Clinical Psychopharmacology 1995; 5: 365–371
   Google Scholar
• Beautrais AL, Joyce PR, Mulder RT. Access to firearms and the risk of suicide: a case control study. Australian and New Zealand Journal of Psychiatry 1996; 30: 741–748
   PubMed Web of Science ®Google Scholar
• Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. American Journal of Epidemiology 1985; 122: 904–914
   PubMed Web of Science ®Google Scholar